345 related articles for article (PubMed ID: 9051086)
1. A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis.
Cazzola M; Borgna-Pignatti C; Locatelli F; Ponchio L; Beguin Y; De Stefano P
Transfusion; 1997 Feb; 37(2):135-40. PubMed ID: 9051086
[TBL] [Abstract][Full Text] [Related]
2. Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassaemia major.
Cazzola M; De Stefano P; Ponchio L; Locatelli F; Beguin Y; Dessi C; Barella S; Cao A; Galanello R
Br J Haematol; 1995 Mar; 89(3):473-8. PubMed ID: 7734344
[TBL] [Abstract][Full Text] [Related]
3. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study.
Pasricha SR; Frazer DM; Bowden DK; Anderson GJ
Blood; 2013 Jul; 122(1):124-33. PubMed ID: 23656728
[TBL] [Abstract][Full Text] [Related]
4. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E
Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
6. Serum transferrin receptor as a marker of erythropoiesis suppression in patients on chronic transfusion.
Tancabelic J; Sheth S; Paik M; Piomelli S
Am J Hematol; 1999 Feb; 60(2):121-5. PubMed ID: 9929103
[TBL] [Abstract][Full Text] [Related]
7. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients.
Angelucci E; Muretto P; Lucarelli G; Ripalti M; Baronciani D; Erer B; Galimberti M; Giardini C; Gaziev D; Polchi P
Blood; 1997 Aug; 90(3):994-8. PubMed ID: 9242528
[TBL] [Abstract][Full Text] [Related]
8. Increased levels of advanced glycation end products positively correlate with iron overload and oxidative stress markers in patients with β-thalassemia major.
Mirlohi MS; Yaghooti H; Shirali S; Aminasnafi A; Olapour S
Ann Hematol; 2018 Apr; 97(4):679-684. PubMed ID: 29318368
[TBL] [Abstract][Full Text] [Related]
9. Iron status and oxidative stress in beta-thalassemia patients in Jakarta.
Laksmitawati DR; Handayani S; Udyaningsih-Freisleben SK; Kurniati V; Adhiyanto C; Hidayat J; Kusnandar S; Dillon HS; Munthe BG; Wirawan R; Soegianto RR; Ramelan W; Freisleben HJ
Biofactors; 2003; 19(1-2):53-62. PubMed ID: 14757977
[TBL] [Abstract][Full Text] [Related]
10. Erythroid bone marrow activity and red cell hemoglobinization in iron sufficient beta-thalassemia heterozygotes as reflected by soluble transferrin receptor and reticulocyte hemoglobin in content. Correlation with genotypes and Hb A(2) levels.
Skarmoutsou C; Papassotiriou I; Traeger-Synodinos J; Stamou H; Ladis V; Metaxotou-Mavrommati A; Stamoulakatou A; Kanavakis E
Haematologica; 2003 Jun; 88(6):631-6. PubMed ID: 12801838
[TBL] [Abstract][Full Text] [Related]
11. New therapeutic targets in transfusion-dependent and -independent thalassemia.
Cappellini MD; Motta I
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
[TBL] [Abstract][Full Text] [Related]
12. [Program of hypertransfusion and chelation with desferrioxamine in 10 patients with thalassemia major].
Albo C; Cabrera J; Dios A; Castro M; Ares C; Constenla I; López D
Sangre (Barc); 1995 Dec; 40(6):441-5. PubMed ID: 8850225
[TBL] [Abstract][Full Text] [Related]
13. Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules.
Chaidos A; Makis A; Hatzimichael E; Tsiara S; Gouva M; Tzouvara E; Bourantas KL
Acta Haematol; 2004; 111(4):189-95. PubMed ID: 15153710
[TBL] [Abstract][Full Text] [Related]
14. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine.
Ehlers KH; Giardina PJ; Lesser ML; Engle MA; Hilgartner MW
J Pediatr; 1991 Apr; 118(4 Pt 1):540-5. PubMed ID: 2007928
[TBL] [Abstract][Full Text] [Related]
15. High transfusion in children with beta-thalassemia/Hb E: clinical and laboratory assessment of 18 cases.
Torcharus K; Withayathawornwong W; Sriphaisal T; Krutvacho T; Arnutti P; Suwanasophorn C
Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():96-9. PubMed ID: 7886617
[TBL] [Abstract][Full Text] [Related]
16. Soluble form of transferrin receptor-1 level is associated with the age at first diagnosis and the risk of therapeutic intervention and iron overloading in patients with non-transfusion-dependent thalassemia.
Ricchi P; Meloni A; Costantini S; Spasiano A; Di Matola T; Pepe A; Cinque P; Filosa A
Ann Hematol; 2017 Sep; 96(9):1541-1546. PubMed ID: 28707012
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary Functions in Children With Thalassemia Major.
Ozyoruk D; Misirlioglu ED
J Pediatr Hematol Oncol; 2015 Nov; 37(8):605-10. PubMed ID: 26422288
[TBL] [Abstract][Full Text] [Related]
18. [Therapeuetic management of patients with thalassemia major].
Thuret I
Bull Soc Pathol Exot; 2001 May; 94(2):95-7. PubMed ID: 11475036
[TBL] [Abstract][Full Text] [Related]
19. Blood transfusion therapy for β-thalassemia major and hemoglobin E β-thalassemia: Adequacy, trends, and determinants in Sri Lanka.
Mettananda S; Pathiraja H; Peiris R; Wickramarathne N; Bandara D; de Silva U; Mettananda C; Premawardhena A
Pediatr Blood Cancer; 2019 May; 66(5):e27643. PubMed ID: 30697927
[TBL] [Abstract][Full Text] [Related]
20. Transferrin receptor 2 is a potential novel therapeutic target for β-thalassemia: evidence from a murine model.
Artuso I; Lidonnici MR; Altamura S; Mandelli G; Pettinato M; Muckenthaler MU; Silvestri L; Ferrari G; Camaschella C; Nai A
Blood; 2018 Nov; 132(21):2286-2297. PubMed ID: 30209118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
